The American Journal of Managed Care

Lower Risk of Recurrent Clostridioides difficile Infections Shown Over Past Decade

A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...
The American Journal of Managed Care

FMT Is Cost Effective for Any Recurrent Clostridioides Difficile Infection, Study Says

Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging ...
Medical Xpress

High-dose VE303 prevents recurrent clostridioides difficile infection

For adults with laboratory-confirmed Clostridioides difficile infection (CDI) at high risk for recurrence, high-dose VE303, a defined bacterial consortium of eight strains of commensal Clostridia, ...
Infection control

Recurrent C Difficile: Evaluating Patients’ Physical, Mental, Social Outlooks

The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments. According to some data, ...
MedPage Today

Oral Microbiome Therapy for Recurrent C. Diff Mostly Holds Up at 6 Months

WASHINGTON -- Extended follow-up of a phase III trial demonstrated continued benefit for an investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infections.
Monthly Prescribing Reference

Ridinilazole Reduces C difficile Infection Recurrence More Effectively Than Vancomycin

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...
Medical Xpress

Experimental vaccine protects against C. diff disease and recurrence

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...
Business Wire

Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an ...

Natural compound shows promise against C difficile while largely sparing healthy gut bacteria

The pathogen Clostridioides difficile (C. difficile) is naturally present in the intestines of many people. When present in ...
Infection control

Clostridioides difficile: Examining Bezlotoxumab and Fecal Microbiota Transplantation

This article first appeared on ContagionLive.com. With newer modalities and therapies for Clostridioides difficile infections (CDI) coming online, there is a need for more studies and an understanding ...
Yahoo Finance

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

Elaris Advances C. difficile Vaccine Beyond Toxin-Only Approaches with Matrivax Asset Acquisition

VIENNA, May 5, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced that it has entered into an ...